Cargando…
A novel octavalent combined Erysipelas, Parvo and Leptospira vaccine provides (cross) protection against infection following challenge of pigs with 9 different Leptospira interrogans serovars
BACKGROUND: In the present study the efficacy and cross protection of a novel ready-to-use combination vaccine, Porcilis® Ery + Parvo + Lepto, against swine leptospirosis, was investigated. The octavalent vaccine contains inactivated antigens of Erysipelothrix rhusiopathiae, Parvovirus and 6 Leptosp...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382398/ https://www.ncbi.nlm.nih.gov/pubmed/28405422 http://dx.doi.org/10.1186/s40813-015-0011-0 |
_version_ | 1782520091178434560 |
---|---|
author | Jacobs, A. Harks, F. Hoeijmakers, M. Segers, R. |
author_facet | Jacobs, A. Harks, F. Hoeijmakers, M. Segers, R. |
author_sort | Jacobs, A. |
collection | PubMed |
description | BACKGROUND: In the present study the efficacy and cross protection of a novel ready-to-use combination vaccine, Porcilis® Ery + Parvo + Lepto, against swine leptospirosis, was investigated. The octavalent vaccine contains inactivated antigens of Erysipelothrix rhusiopathiae, Parvovirus and 6 Leptospira interrogans sensu lato strains of serogroups Canicola, Icterohaemorrhagiae, Grippotyphosa, Australis (Bratislava), Pomona and Tarassovi. In this study ninety pigs were vaccinated twice with Porcilis® Ery + Parvo + Lepto at six and ten weeks of age and ninety age and source-matched animals served as unvaccinated control. Two weeks after booster vaccination, groups of vaccinated and control pigs (ten pigs per group) were challenged with fresh virulent cultures of either of the nine different challenge strains. Compared to the vaccine strains the challenge strains were heterologous strains of the same serovar or of a different serovar within the same serogroup. The challenge strains tested were of serovar Canicola, Icterohaemorrhagiae, Copenhageni (serogroup Icterohaemorrhagiae), Grippotyphosa, Bananal/Liangguan (serogroup Grippotyphosa), Pomona, Tarassovi and Vughia (serogroup Tarassovi). RESULTS: After the different challenges most control animals became leptospiraemic for 2–7 days. The vaccinated pigs remained blood culture negative except for two animals after serovar Icterohaemorrhagiae and two animals after serovar Tarassovi challenge which became leptospiraemic for only 1 day. The incidence of Leptospiraemia (as determined by blood culture) was significantly less in vaccinates compared to the controls after all challenges. The vaccine also prevented renal infection and urinary shedding after serovar Canicola challenge. The other serovars did not induce detectable renal infection or urinary shedding. CONCLUSION: The present study demonstrates that the new combination vaccine Porcilis® Ery + Parvo + Lepto induces significant (cross) protection against nine different serovars within the serogroups Canicola, Icterohaemorrhagiae, Grippotyphosa, Australis (Bratislava), Pomona and Tarassovi. |
format | Online Article Text |
id | pubmed-5382398 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-53823982017-04-12 A novel octavalent combined Erysipelas, Parvo and Leptospira vaccine provides (cross) protection against infection following challenge of pigs with 9 different Leptospira interrogans serovars Jacobs, A. Harks, F. Hoeijmakers, M. Segers, R. Porcine Health Manag Research BACKGROUND: In the present study the efficacy and cross protection of a novel ready-to-use combination vaccine, Porcilis® Ery + Parvo + Lepto, against swine leptospirosis, was investigated. The octavalent vaccine contains inactivated antigens of Erysipelothrix rhusiopathiae, Parvovirus and 6 Leptospira interrogans sensu lato strains of serogroups Canicola, Icterohaemorrhagiae, Grippotyphosa, Australis (Bratislava), Pomona and Tarassovi. In this study ninety pigs were vaccinated twice with Porcilis® Ery + Parvo + Lepto at six and ten weeks of age and ninety age and source-matched animals served as unvaccinated control. Two weeks after booster vaccination, groups of vaccinated and control pigs (ten pigs per group) were challenged with fresh virulent cultures of either of the nine different challenge strains. Compared to the vaccine strains the challenge strains were heterologous strains of the same serovar or of a different serovar within the same serogroup. The challenge strains tested were of serovar Canicola, Icterohaemorrhagiae, Copenhageni (serogroup Icterohaemorrhagiae), Grippotyphosa, Bananal/Liangguan (serogroup Grippotyphosa), Pomona, Tarassovi and Vughia (serogroup Tarassovi). RESULTS: After the different challenges most control animals became leptospiraemic for 2–7 days. The vaccinated pigs remained blood culture negative except for two animals after serovar Icterohaemorrhagiae and two animals after serovar Tarassovi challenge which became leptospiraemic for only 1 day. The incidence of Leptospiraemia (as determined by blood culture) was significantly less in vaccinates compared to the controls after all challenges. The vaccine also prevented renal infection and urinary shedding after serovar Canicola challenge. The other serovars did not induce detectable renal infection or urinary shedding. CONCLUSION: The present study demonstrates that the new combination vaccine Porcilis® Ery + Parvo + Lepto induces significant (cross) protection against nine different serovars within the serogroups Canicola, Icterohaemorrhagiae, Grippotyphosa, Australis (Bratislava), Pomona and Tarassovi. BioMed Central 2015-11-17 /pmc/articles/PMC5382398/ /pubmed/28405422 http://dx.doi.org/10.1186/s40813-015-0011-0 Text en © Jacobs et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Jacobs, A. Harks, F. Hoeijmakers, M. Segers, R. A novel octavalent combined Erysipelas, Parvo and Leptospira vaccine provides (cross) protection against infection following challenge of pigs with 9 different Leptospira interrogans serovars |
title | A novel octavalent combined Erysipelas, Parvo and Leptospira vaccine provides (cross) protection against infection following challenge of pigs with 9 different Leptospira interrogans serovars |
title_full | A novel octavalent combined Erysipelas, Parvo and Leptospira vaccine provides (cross) protection against infection following challenge of pigs with 9 different Leptospira interrogans serovars |
title_fullStr | A novel octavalent combined Erysipelas, Parvo and Leptospira vaccine provides (cross) protection against infection following challenge of pigs with 9 different Leptospira interrogans serovars |
title_full_unstemmed | A novel octavalent combined Erysipelas, Parvo and Leptospira vaccine provides (cross) protection against infection following challenge of pigs with 9 different Leptospira interrogans serovars |
title_short | A novel octavalent combined Erysipelas, Parvo and Leptospira vaccine provides (cross) protection against infection following challenge of pigs with 9 different Leptospira interrogans serovars |
title_sort | novel octavalent combined erysipelas, parvo and leptospira vaccine provides (cross) protection against infection following challenge of pigs with 9 different leptospira interrogans serovars |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382398/ https://www.ncbi.nlm.nih.gov/pubmed/28405422 http://dx.doi.org/10.1186/s40813-015-0011-0 |
work_keys_str_mv | AT jacobsa anoveloctavalentcombinederysipelasparvoandleptospiravaccineprovidescrossprotectionagainstinfectionfollowingchallengeofpigswith9differentleptospirainterrogansserovars AT harksf anoveloctavalentcombinederysipelasparvoandleptospiravaccineprovidescrossprotectionagainstinfectionfollowingchallengeofpigswith9differentleptospirainterrogansserovars AT hoeijmakersm anoveloctavalentcombinederysipelasparvoandleptospiravaccineprovidescrossprotectionagainstinfectionfollowingchallengeofpigswith9differentleptospirainterrogansserovars AT segersr anoveloctavalentcombinederysipelasparvoandleptospiravaccineprovidescrossprotectionagainstinfectionfollowingchallengeofpigswith9differentleptospirainterrogansserovars AT jacobsa noveloctavalentcombinederysipelasparvoandleptospiravaccineprovidescrossprotectionagainstinfectionfollowingchallengeofpigswith9differentleptospirainterrogansserovars AT harksf noveloctavalentcombinederysipelasparvoandleptospiravaccineprovidescrossprotectionagainstinfectionfollowingchallengeofpigswith9differentleptospirainterrogansserovars AT hoeijmakersm noveloctavalentcombinederysipelasparvoandleptospiravaccineprovidescrossprotectionagainstinfectionfollowingchallengeofpigswith9differentleptospirainterrogansserovars AT segersr noveloctavalentcombinederysipelasparvoandleptospiravaccineprovidescrossprotectionagainstinfectionfollowingchallengeofpigswith9differentleptospirainterrogansserovars |